)
Visual
test
Marksans Pharma
Marksans Pharma (MARKSANS) investor relations material
Marksans Pharma Q3 25/26 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 25/26 earnings summary6 Feb, 2026
Executive summary
Q3 FY26 operating revenue reached INR 754 crore, up 10.6% YoY, driven by strong execution, robust US order book, and seasonal demand, with margin expansion from lower raw material costs and favorable currency movements.
UK business stabilized after prior pricing pressures, aided by new launches and currency tailwinds.
New subsidiaries were established in Ireland and Canada to strengthen global presence and support long-term growth.
Standalone and consolidated unaudited financial results for the quarter and nine months ended 31 December 2025 were reviewed and approved by the Board, with auditors expressing an unmodified conclusion.
Financial highlights
Q3 FY26 consolidated revenue: INR 754.4 crore (up 10.6% YoY); 9M FY26 revenue: INR 2,094.8 crore (up 9.54% YoY); US & North America: INR 412.4 crore (up 16.9% YoY); UK & EU: INR 258.2 crore (flat YoY); Australia/NZ: INR 61.4 crore (up 30.1% YoY).
Gross profit: INR 438.2 crore (up 14.3% YoY); gross margin: 58.1% (up 184 bps YoY); EBITDA: INR 160.7 crore (up 23.2% YoY); EBITDA margin: 21.3% (up 217 bps YoY).
Profit after tax: INR 113.7 crore (up 8.2% YoY); EPS: INR 2.5.
Cash from operations (9M): INR 263.2 crore; Capex: INR 97 crore; R&D spend: INR 62 crore (3% of revenue); cash balance: INR 824.2 crore; company remains debt-free.
Standalone revenue for the quarter: INR 3,397.29 million; standalone profit after tax: INR 609.12 million.
Outlook and guidance
US order book remains strong at $220M+, supporting optimism for near-term growth; targeting 20% growth in US for the upcoming year.
Strategic goal to reach INR 4,000 crore revenue in 2–3 years, with INR 5,000 crore as the next milestone.
Management expects growth momentum to continue for the rest of FY26, aiming for INR 3,000 crore revenue in the near term.
Europe and Canada expected to contribute meaningfully in 3–5 years, with 2026 as a turning point for Europe via M&A.
Employee costs expected to stabilize as hiring plateaus and capacity utilization rises.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- 6 FebHTOO
Resale registration for 71,429 shares via warrant, with proceeds only on exercise; financial risks persist. - 6 FebVSAT
Q3 revenue up 3% to $1.16B, net income $25M, strong cash flow, Ligado boost, satellite focus. - 6 FebWEC
Targets 7–8% EPS growth, $37.5B capex, and coal exit by 2032 amid surging data center demand. - 6 FebBR
Q2 FY26 recurring revenue grew 8% and adjusted EPS guidance was raised to 9-12%. - 6 FebFFWM
Merger vote includes new non-voting stock class with limited conversion and no voting rights. - 6 FebKKR
Charter amendments seek to modernize governance and establish one share, one vote by 2026. - 6 FebARI
Proposed $9B real estate loan portfolio acquisition highlights disciplined, long-term strategy. - 6 FebSMCI
Q2 revenue jumped 123% to $12.7B, with FY26 guidance raised to at least $40B. - 6 FebRJF
Record revenues and assets, higher dividend, and acquisitions despite lower net income. - 6 FebFFIE
Raising capital for global EV and AI expansion, with regulatory and dilution risks highlighted.
Next Marksans Pharma earnings date
Q4 25/2619 May, 2026
Marksans Pharma
Next Marksans Pharma earnings date
Q4 25/2619 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Marksans Pharma Limited is a pharmaceutical company engaged in the research, manufacturing, and marketing of generic pharmaceutical formulations. The company produces a wide range of dosage forms including tablets, capsules, liquids, and ointments across therapeutic areas such as pain management, gastrointestinal, cardiovascular, and anti-infective segments. It serves regulated and semi-regulated markets including the United States, Europe, Australia, and emerging regions. Marksans Pharma Limited operates manufacturing facilities compliant with global regulatory standards and offers contract manufacturing services. The company is headquartered in Mumbai, India, and its shares are listed on the BSE.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage